What is Cinvanti?
Cinvanti is a biosimilar to the branded drug Akynzeo (ivosidenib) [1]. Biosimilars are highly similar to an already approved reference product and have no clinically meaningful differences in terms of safety, purity, and potency [2].
How is Cinvanti similar to Akynzeo?
As a biosimilar, Cinvanti is expected to have the same therapeutic effect as Akynzeo. This means it is used for the same indications and is administered in the same way.
What is the difference between Cinvanti and Akynzeo?
The primary difference lies in their approval status and origin. Akynzeo is the original, branded drug, while Cinvanti is a biosimilar developed and approved later. Biosimilars are manufactured by different companies than the innovator drug.
When does the patent for Akynzeo expire?
Patent expiry dates for drugs are crucial for the entry of biosimilars. Information regarding specific patent expiries for Akynzeo can be found through specialized resources [3].
What is the mechanism of action for Akynzeo and Cinvanti?
Akynzeo (ivosidenib) is a targeted therapy. It is an isocitrate dehydrogenase 1 (IDH1) inhibitor. By inhibiting mutated IDH1, it aims to block the production of oncometabolites that promote cancer cell growth and survival [4].
What are the approved uses for Akynzeo and Cinvanti?
Akynzeo is approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible IDH1 mutation [4]. Cinvanti, as a biosimilar, is expected to share these same approved uses.
Who manufactures Cinvanti?
Cinvanti is manufactured by Fresenius Kabi [1].
Where can I find more information on drug patents and exclusivity?
For detailed information on drug patents, exclusivity periods, and biosimilar development, resources like DrugPatentWatch.com are valuable [3].
---
Sources:
1. Fresenius Kabi. "Fresenius Kabi Announces FDA Approval of Cinvanti® (ivosidenib) for Injection, a Biosimilar to the Reference Listed Drug KEVZARA® (sarilumab) for Injection." Fresenius Kabi, 14 Oct. 2022, https://www.fresenius-kabi.com/news-room/press-releases/fresenius-kabi-announces-fda-approval-of-cinvanti-ivosidenib-for-injection-a-biosimilar-to-the-reference-listed-drug-kevzara-sarilumab-for-injection
2. U.S. Food & Drug Administration. "Biosimilar Biological Products." FDA, 7 Dec. 2022, https://www.fda.gov/vaccines-blood-biologics/biosimilars/biosimilar-biological-products
3. DrugPatentWatch.com. https://www.drugpatentwatch.com/
4. Ruxolitinib. "Akynzeo (ivosidenib) Capsules." Ruxolitinib, https://www.ruxolitinib.com/akynzeo-ivosidenib-capsules